ONCBIOMUNE LLC Company Brief Developing Targeted Therapies to Fight Cancer www.oncbiomune.com

MANAGEMENT

CEO / Medical Director Robert Elliott, M.D., Ph.D.

President / Director of Research Jonathan Head, Ph.D.

Chief Financial Officer/ EVP Andrew A. Kucharchuk, MBA

INDUSTRY

Immunotherapy / Cancer Therapy Research & Development

DRUGS IN DEVELOPMENT

Clinical Development

Prostate Cancer Vaccine Breast Cancer Vaccine Targeted Chemotherapy Drugs (3)

NUMBER OF EMPLOYEES: 5

USE OF FUNDS

Clinical development and licensing activities. Priority on Phase I/II for prostate cancer vaccine; Phase I and II for breast cancer vaccine; Phase I for lead innovative chemotherapy drug.

OncBioMune LLC India Contact: Godwyn Francis 17050 Medical Center Drive, 4

th Floor Phone: +91-787-501-6957

Baton Rouge, LA 70816 Email: godwyn@aagami.net

CONFIDENTIAL

COMPANY DESCRIPTION – OncBioMune, LLC is a biotechnology company developing

cancer vaccines and targeted cancer therapies. The company’s founders, Robert Elliott, M.D.,

Ph.D. and Jonathan Head, Ph.D., have developed a portfolio of promising cancer therapies

that includes two vaccines for patients with breast and prostate cancer (both evaluated in

Phase I/II clinical studies) and four transferrin based novel drugs (three evaluated in Phase I

studies) that attack cancer tumors specifically and therefore have greater efficacy and less

toxicity than conventional chemotherapy.

Their work has been conducted at the Elliott-Elliott-Head Breast Cancer Research and

Treatment Center (EEH BCRTC) in Baton Rouge, where they treat patients with cancer daily.

OncBioMune was established in 2005 to further the clinical development of the cancer

treatments and to pursue licensing or acquisition of its therapies and proprietary technologies.

BUSINESS STRATEGY – OncBioMune will develop its cancer therapies to the point where

they hold significant value for licensing or acquisition. Initial investment will be used to

confirm the results already demonstrated in clinical trials at EEH BCRTC with independently

conducted Phase I and Phase II clinical trials. The company will then license or sell the

products or collaborate with pharmaceutical or biotech companies for late stage development

(Phase III clinical trials, FDA approval) and commercialization.

CLINICAL STRATEGY – The prostate cancer vaccine is the company’s most developed

product. A Phase I /II clinical trial at EEH BCRT demonstrated significant decreases in the PSA levels of all patients and that the vaccine was well tolerated. Initial congressional funding of $1 million and support from the Naval Health Research Center has allowed development of methods for PSA protein synthesis and the Phase 1 clinical trial design. In 2009, OncBioMune received a second round of funding of $2.25 Million in congressional funding for completion of PSA protein manufacturing under cGMP and final IND submission. Then In 2010, the company received a third round of funding to fully fund a phase 1a/1b clinical trial that will begin August 2012 and will be hosted by UCSD. The company is currently finishing the administrative requirements to begin the trial.

.

MANAGEMENT – OncBioMune is led by two key individuals with extensive experience in

patient care, research, and the clinical development of therapies. CEO and Medical Director

Robert Elliott, M.D., Ph.D., founded the Elliott-Elliott-Head Breast Cancer Research and

Treatment Center in 1973 and is considered an expert in diseases of the breast as well as an

innovator in cancer therapy and research. President and Director of Research Jonathan

Head, Ph.D. is a prominent tumor cell biologist, specializing in cell culture and human clinical

research in immunotherapy and innovative chemotherapy. He has served as the director of

research and development for several companies and has led the preclinical and clinical

development of the company’s therapies.

MARKET OPPORTUNITY – Breast, Prostate and Ovarian cancer represent three of the largest

markets for cancer treatment. Breast cancer is the leading cause of cancer among women

with an estimated market size of $11.5 Billion by 2011. Prostate cancer is one of the leading

cancers among men with a market size of $ 5 Billion expected by 2011. The market for

ovarian cancer is also expected to grow substantially to an estimated $ 2.5 Billion by 2011.

COMPETITION – Competition for the company’s cancer vaccines and targeted therapies

comes from FDA-approved conventional chemotherapy agents and a small number of

monoclonal antibodies. Breast cancer vaccines currently in development include ADVEXIN®

(Introgen Therapeutics), Phase II clinical trial ongoing; and TROVAX® (Oxford Biomedica),

Phase I trial completed. Prostate cancer vaccines in development include PROVENGE®

(Dendreon Corporation), FDA approval GVAX® (Cell Genesys), Phase III trial ongoing; and

PROSTVAC®-VF (Therion Biologics) Phase II trial ongoing.

To be read in conjunction with OncBiomune Presentation

ONCBIOMUNE LLC Technology Description Developing Targeted Therapies to Fight Cancer www.oncbiomune.com

Targeted Cancer Treatments

Our Solution / Mechanism of Action Oncbiomune has clinical studies on three targeted chemotherapeutic agents and is in preclinical development of a fourth. These agents use our transferrin-based technology to deliver toxic metals and chemotherapeutic agents that interfere with the aberrant iron metabolism of cancer cells. Cancer cells require high concentrations of iron to carry on cell division and grow. Therefore transferrin, the transporter of iron in the body, can be used to carry toxic heavy metals and chemotherapeutic agents directly into cancer cells.

These drugs, used alone or in combination, have demonstrated tremendous cancer cell killing with very little affect on normal cells and minimal side effects. They have also been shown to potentiate the effect and lessen the toxicity of conventional chemotherapy when given with it.

CT (Cisplatin Transferrin) – Phase I and II GT (Gallium Transferrin) – Phase I and II DGT (Doxorubicin Gallium Transferrin) – Phase I and II PGT (Paclitaxel Gallium Transferrin) - Preclinical PA (Paclitaxel Albumin) – Preclinical

Intellectual Property- Patent application has been submitted for PGT and PA.

PGT application: pending in U.S., Canada, and Europe only

Whole-cell vaccine application: Pending internationally and awaiting ex-U.S. filing

PSA vaccine application: pending in U.S. and internationally

Highlights of Previous Preclinical and Clinical Studies The transferrin-based technologies are at various levels of development from pre-clinical (paclitaxel gallium transferrin (PGT) and paclitaxel albumin (PA)) to Phase II trials (cisplatinum-transferrin or CT, gallium-transferrin or GT, and doxorubicin-gallium-transferrin or DGT). PGT is our best candidates for commercial development due to their high cytotoxicity to cancer cells in culture.

CT, GT and DGT have each been tested in Phase I and II clinical trials without any major toxicity. In a Phase I/II clinical trial of CT, there was one complete response and three partial responses for an overall response rate of 36% (4 of 11 patients). Multiple, large doses of the drug were given safely without causing an immune response to the transferrin. This will allow prolonged treatment of patients with these drugs. GT and DGT have been tested only in combination with other chemotherapies or in combined chemo-immunotherapy. This makes it hard to quantitate what these two drugs contribute to the overall response to therapy. Additional Phase I/II clinical trials by outside investigators are needed.

Clinical Development Strategy The first IND will be filed for PGT (paclitaxel gallium transferrin) for the treatment of advance ovarian cancer. The company believes PGT is the strongest of the targeted compounds it has developed.

CT, GT, DGT, PGT and PA can be used to treat other cancers. A strategy for completing Phase I and II clinical trials of these compounds in other cancers at external institutions will be established as other clinical development milestones are met.

Market Opportunity / Clinical Need Breast cancer represent one of the largest markets for cancer treatment. The U.S. breast cancer treatment market consists of 13 drugs approved for use by the FDA. During 2004, just 12 of these drugs contributed to sales of more than $6.2 billion. The 13

th drug for cancer therapy, Abraxane™, was approved by the FDA in January 2005. Ovarian cancer survival after

chemotherapy of advanced disease is very low and introduction of new drugs for treatment of ovarian cancer will be needed to improve overall survival.

Competition / Drugs in Development Several antibodies and small molecules have been described as targeted therapies, but have been found to have greater than expected toxicities. On a broad scale, competition for the company’s targeted therapies comes from conventional chemotherapy agents, which are not specific to tumors and therefore must be dosed at high levels and travel throughout the body in order to be effective in killing cancer cells.

Please contact godwyn@aagami.net or dinesh@aagami.net for more information.

OncBioMune LLC India Contact: Godwyn Francis 17050 Medical Center Drive, 4

th Floor Phone: +91-787-501-6957

Baton Rouge, LA 70816 Email: godwyn@aagami.net